Instruction for use: Provera

Active substance Medroxyprogesterone

ATX code G03DA02 Medroxyprogesterone

Pharmacological groups

Estrogens, gestagens; Their homologues and antagonists

Antineoplastic hormonal agents and hormone antagonists

Nosological classification (ICD-10)

C50 Malignant neoplasm of breast

Cancer of the nipple and areola of the breast, Breast carcinoma, The hormone-dependent form of recurrent breast cancer in women in menopause, Hormone-dependent breast cancer, Disseminated breast carcinoma, Disseminated Breast Cancer, Malignant breast cancer, Malignant neoplasm of breast, Contralateral breast cancer, Locally advanced or metastatic breast cancer,Locally-distributed breast cancer, Locally-recurring breast cancer, Metastatic breast carcinoma, Metastasis of breast tumors, Metastatic breast carcinoma, Inoperable breast carcinoma, Incompatible breast cancer, Breast cancer in women with metastases, Breast cancer in men with metastases, Breast Cancer, Breast cancer in men, Mammary cancer, Breast cancer with distant metastases, Breast cancer in postmenopausal women, Breast cancer hormone-dependent, Breast cancer with local metastases, Breast cancer with metastases, Breast cancer with regional metastases,Breast cancer with metastases, Common hormone-dependent forms of breast cancer, Common Breast Cancer, Recurrent Breast Cancer, Recurrence of breast tumors, Breast cancer, Estrogen-dependent breast cancer, Estrogen-Dependent Breast Cancer, Disseminated breast cancer with overexpression of HER2, Tumors of the mammary glands

C54.1 Malignant neoplasm of endometrium

Recurrent inoperable endometrial cancer, Endometrial cancer, Metastatic endometrial carcinoma, Metastatic Endometrial Cancer, Endometrial carcinoma, Recurrent carcinomas of the endometrium, Recurrent endometrial cancer

C64 Malignant neoplasm of kidney, except for renal pelvis

Wilms swelling, Kidney Cancer, Metastatic Renal Cell Carcinoma, Renal carcinoma, Inoperable kidney carcinomas, Metastatic kidney carcinoma, Metastatic Renal Cell Carcinoma, Wilms tumor, Wilms swelling, Adenomyosarcoma, Adenomyocystosarcoma, Adenosarcoma of the kidney, Kidney Cancer, Common renal cell carcinoma, Nephroblastoma, Nephroma, Embryonal nephroma, Recurrent carcinoma of the kidney, Birch-Hirschfeld Tumor, Common renal cell carcinoma, Tumors of the kidney

Composition and form of release

Tablets 1 table.

Medroxyprogesterone acetate 100 mg \ 500 mg

Auxiliary substances: corn starch; Magnesium stearate; MCC; gelatin; Polyethylene glycol 400; Sodium starch; Docusate sodium (85%) with sodium benzoate (15%)

In a planar cell pack of 10; In a pack of cardboard 3 packs.

Description of dosage form

Tablets of 100 mg: white, round, flat with a notch.

Tablets of 500 mg: white, oblong, biconvex.

pharmachologic effect

Pharmacological action - antitumor, progestogen.

Indications

Hormone-dependent forms of recurrent breast cancer in women in menopause (palliative care), recurrent and / or metastatic endometrial cancer, kidney (additional and / or palliative treatment).

Contraindications

Hypersensitivity, pregnancy.

Side effects

From the nervous system and sensory organs: dizziness, headache, nervousness, sleep disorders, drowsiness, weakness, depression.

From the cardiovascular system and blood (hematopoiesis, hemostasis): thromboembolism, thrombophlebitis.

Allergic reactions: rashes, hives; In some cases - anaphylactoid reactions.

Other: nausea, tenderness of the mammary glands, galactorrhea, fever, symptomatic complex Itenko-Cushing (with prolonged intake of high doses).

Dosing and Administration

Inside, with recurrent breast cancer in women in menopause at 400-1200 mg / day, with recurrent endometrial cancer and kidneys - 200-600 mg / day.

Storage conditions

At a temperature of 15-30 ° C.

Keep out of the reach of children.

Shelf life

5 years.

Do not use after the expiry date printed on the package.